CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 57 enrolled
Drug / intervention
ALXN1840 +2 moredrug
Likely dose
ALXN1840 120 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04560816
NCT04560816Phase 1Completed
CompareCT.gov

A Randomized, 3-Treatment, 3-Period, 6-Sequence, Crossover, Placebo- and Active-Controlled, Double-Blind for ALXN1840 (Open-Label for Moxifloxacin) Thorough QT/QTc Study to Evaluate ALXN1840 on Cardiac Repolarization in Healthy Adults

Alexion Pharmaceuticals, Inc.·interventional·Posted Sep 23, 2020·Updated Aug 14, 2023

In Brief

A Phase 1 clinical trial evaluating ALXN1840, Placebo, and 1 other intervention for Healthy. Completed, enrolled 57 participants across 1 site.

Detailed Summary

This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsPPD Development, LP, ERT: Clinical Trial Technology Solutions

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedSep 23, 2020
Enrollment StartJul 24, 2020
Primary CompletionMar 24, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.8 years ago

Interventions

ALXN1840drug

ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).

Placebodrug

Placebo will be administered orally.

Moxifloxacindrug

Moxifloxacin (400 milligrams) will be administered orally.